The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Learn more about this approval in Johnson & Johnson’s news release ... and potentially life-changing treatment option. “FDA’s approval of IMAAVY TM (nipocalimab-aahu) is an important step ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in ...

The drug also showed a favorable safety profile, with adverse events comparable to placebo and no new safety signals observed. Liza O’Dowd, MD, of Johnson & Johnson, emphasized the potential of ...